Article Text

Download PDFPDF
DI-004 Evaluation of the use of pazopanib in a tertiary-level hospital
  1. V Alonso Castro,
  2. BM Escudero Vilaplana,
  3. C Folguera Olias,
  4. A Diez Alcantara,
  5. A Torralba Arranz
  1. Hospital Universitario Puerta de Hierro Majadahonda, Farmacia Hospitalaria, Majadahonda (Madrid), Spain


Background Pazopanib is a protein kinase inhibitor. It is indicated in adults for the treatment of advanced Renal Cell Carcinoma (RCC) and the treatment of patients with particular subtypes of advanced Soft Tissue Sarcoma (STS).

Purpose To evaluate the effectiveness and safety of pazopanib in a tertiary care hospital.

Materials and methods Descriptive observational study of the use of pazopanib since February 2011. The following data were recorded in the medical history in the Selene application (medical history software): sex, age at which the treatment was initiated, pathology, indication, line of treatment, prescribing service and adverse reactions.

Results 19 patients were analysed (57% male), with an average age of starting treatment of 54 years (24–80 years). 16 of them met the approved criteria: 10 metastatic RCC (6 were first line and 4 second line) and 6 STSs (3 second line, 2 third line and 1 fourth line). In adddition, 2 were off-label: 2 metastatic thyroid carcinoma (second line) and 1 metastatic pancreatic adenocarcinoma (third line).

Prescriber services were oncology (16 patients), endocrinology (2) and urology (1).

Only 7 patients continue on treatment. The average duration of treatment was 244 days (14–650 days) and the reasons for dropout were: tumour progression (6), intolerance to treatment (5), no available data (1).

11 patients presented adverse reactions. Most were: asthenia (3), weight loss (2), diarrhoea (3), nausea (1), esophagitis (1), muscle pain (2), hand-foot syndrome (1), hypertension (2), ALT/AST elevation (3), impaired renal function (2), hypokalaemia (1), visual loss (1), lymphopenia (1), anaemia (1), skin graft necrosis (1).

Conclusions The average duration of the treatment (244 days) and the fact that seven patients continue treatment reveals that pazopanib is effective in controlling disease progression.

Oral administration and the fact that most adverse effects recorded are mild provides advantages over other therapeutic alternatives.

No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.